Hanmi Pharm's Blockbuster Hypertension Combination Drug 'Amozaltan' Begins Full-Scale Entry into China

Beijing Hanmi Pharm, Approval for Amozaltan Sales in China
Nationwide Launch Across China in October This Year

Hanmi Pharm Amozaltan.

[Asia Economy Reporter Lee Gwan-joo] Hanmi Pharmaceutical's blockbuster product 'Amozantan' is entering the Chinese market. Amozantan is the first combination drug product from a Korean pharmaceutical company to enter the Chinese hypertension treatment market.

Hanmi Pharmaceutical Group's local Chinese subsidiary, Beijing Hanmi Pharmaceutical, announced on the 10th that it has received marketing approval for Amozantan from the National Medical Products Administration (NMPA) of China, and after preparing marketing strategies, it will begin sales nationwide in China starting this October.

The approved dosages are two combination products containing the hypertension treatment CCB ingredient amlodipine and the ARB ingredient losartan, in 5/50 mg and 5/100 mg formulations respectively.

Amozantan, the first combination new drug developed by a Korean pharmaceutical company, combines two ingredients (amlodipine + losartan) to treat hypertension. Hanmi Pharmaceutical has surpassed cumulative sales of 1 trillion KRW over the past 10 years with the 'Amozantan Family,' which includes Amozantan, Amozantan Plus, Amozantan Q, and Amozantan XQ.

According to the National Health Commission of China, the prevalence of hypertension among the Chinese population aged 18 and over is about 32%, approximately 380 million people, and it is rapidly increasing every year. Given the rapid growth of the hypertension treatment market in China, Amozantan's entry is attracting attention.

Beijing Hanmi Pharmaceutical plans to diversify its main product portfolio by expanding its current business model, which is centered on pediatric medicines, to include adult medicines, using the approval of Amozantan's marketing authorization as an opportunity. Beijing Hanmi Pharmaceutical also plans to apply for marketing approval from Chinese authorities for 'Rosujet,' another blockbuster product from Hanmi Pharmaceutical.

Lim Hae-ryong, General Manager of Beijing Hanmi Pharmaceutical, said, "We are very pleased to be able to launch Amozantan, a representative product of Hanmi Pharmaceutical, in the Chinese market," and added, "We will do our best to continue the Amozantan success story in China by fully utilizing Beijing Hanmi's specialized local marketing know-how."

This content was produced with the assistance of AI translation services.